METHOD OF TREATING PROSTATIC CANCER WITH ANTAGONIST OF GONADOTROPIN-GRAINING HORMONE (GnRH) DEGARELIX

摘要

The invention provides a method for treating prostate cancer in a subject, comprising administering degarelix to said subject in an initial dose of 160 to 320 mg and then in a maintenance dose of 60 to 160 mg once every 20-36 days, where treatment is accompanied by a reduced frequency and / or the likelihood of one or more of the disorders of the urinary or renal system in the subject being treated.